• InMed Pharmaceuticals reached a definitive all-stock merger agreement with privately held Mentari Therapeutics, combining Mentari’s migraine-prevention pipeline with InMed’s public listing.
• The combined company is expected to operate as Mentari Therapeutics, remaining listed on the Nasdaq Capital Market under a new ticker symbol.
• Mentari also completed an oversubscribed US$ 290 million private placement intended to fund operations through 2028.
• First-in-human regulatory filings are expected in mid-2026 for MT-001, an anti-PACAP antibody, followed by 1Q 2027 for MT-002, an anti-CGRP x PACAP bispecific antibody.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605190800PR_NEWS_USPR_____PH61096) on May 19, 2026, and is solely responsible for the information contained therein.